ATRC logo

ATRC
Atricure Inc

387
Mkt Cap
$1.7B
Volume
355,536.00
52W High
$43.11
52W Low
$28.29
PE Ratio
-54.69
ATRC Fundamentals
Price
$33.25
Prev Close
$34.18
Open
$34.77
50D MA
$34.98
Beta
1.06
Avg. Volume
484,993.74
EPS (Annual)
-$0.9517
P/B
3.47
Rev/Employee
$357,928.46
Loading...
Loading...
News
all
press releases
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?
Here is how AtriCure (ATRC) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.
Zacks·15h ago
News Placeholder
More News
News Placeholder
AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...
Business Wire·3d ago
News Placeholder
AtriCure, Inc. $ATRC Shares Sold by Calamos Advisors LLC
Calamos Advisors LLC reduced its position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 88.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and...
MarketBeat·5d ago
News Placeholder
Connor Clark & Lunn Investment Management Ltd. Raises Holdings in AtriCure, Inc. $ATRC
Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 18.2% in the second quarter, according to the company in its most recent...
MarketBeat·7d ago
News Placeholder
Acadian Asset Management LLC Has $6.69 Million Stock Position in AtriCure, Inc. $ATRC
Acadian Asset Management LLC boosted its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 4.5% in the 2nd quarter, according to its most recent filing with the Securities...
MarketBeat·8d ago
News Placeholder
AtriCure (ATRC) Loses 13.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for AtriCure (ATRC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·14d ago
News Placeholder
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings (Revised)
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·15d ago
News Placeholder
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Zacks·17d ago
News Placeholder
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·22d ago
News Placeholder
AtriCure (ATRC) Reports Q3 Loss, Beats Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of +90.91% and +2.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·22d ago

Latest ATRC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.